Polypharmacy in Parkinson’s disease: risks and benefits with little evidence

Aldehyde adducts inhibit 3,4-dihydroxyphenylacetaldehyde-induced α-synuclein aggregation and toxicity: implication for Parkinson neuroprotective therapy

(2018) Vijaya B. Kumar et al.   EUROPEAN JOURNAL OF PHARMACOLOGY

Repeated-Dose Oral N-Acetylcysteine in Parkinson's Disease: Pharmacokinetics and Effect on Brain Glutathione and Oxidative Stress

(2017) Lisa D. Coles et al.   JOURNAL OF CLINICAL PHARMACOLOGY

Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial

(2017) Dilan Athauda et al.   LANCET

Nortriptyline inhibits aggregation and neurotoxicity of alpha-synuclein by enhancing reconfiguration of the monomeric form

(2017) Timothy J. Collier et al.   NEUROBIOLOGY OF DISEASE

Association of plasma homocysteine, vitamin B12 and folate levels with cognitive function in Parkinson’s disease: A meta-analysis

(2017) Yi Xie et al.   NEUROSCIENCE LETTERS

Biological and Clinical Implications of Comorbidities in Parkinson’s Disease

(2017) Jose A. Santiago et al.   Frontiers in Aging Neuroscience

L-DOPA-induced hyperhomocysteinemia in Parkinson's disease: Elephant in the room

(2016) Rajib Paul et al.   BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS

Calcium Channel Antagonists as Disease-Modifying Therapy for Parkinson’s Disease: Therapeutic Rationale and Current Status

(2016) Tara Swart et al.   CNS DRUGS

Rivastigmine for gait stability in patients with Parkinson's disease (ReSPonD): a randomised, double-blind, placebo-controlled, phase 2 trial

(2016) Emily J Henderson et al.   LANCET NEUROLOGY

Inhibitors of MAO-A and MAO-B in Psychiatry and Neurology

(2016) John P. M. Finberg et al.   Frontiers in Pharmacology

Impact of Rivastigmine on Cognitive Dysfunction and Falling in Parkinson's Disease Patients

(2015) Zhenguang Li et al.   EUROPEAN NEUROLOGY

Pioglitazone in early Parkinson's disease: a phase 2, multicentre, double-blind, randomised trial

(2015)   LANCET NEUROLOGY

Laying the foundations for disease-modifying therapies in PD

(2015) Patrik Brundin et al.   Nature Reviews Neurology

Depression—risk factor or early symptom in Parkinson disease?

(2015) Albert F. Leentjens   Nature Reviews Neurology

Ambroxol improves lysosomal biochemistry in glucocerebrosidase mutation-linked Parkinson disease cells

(2014) Alisdair McNeill et al.   BRAIN

Treatment effect of memantine on survival in dementia with Lewy bodies and Parkinson's disease with dementia: a prospective study

(2014) K. Stubendorff et al.   BMJ Open

Proton Pump Inhibitor and Histamine 2 Receptor Antagonist Use and Vitamin B12Deficiency

(2013) Jameson R. Lam et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Shared dysregulated pathways lead to Parkinson's disease and diabetes

(2013) Jose A. Santiago et al.   TRENDS IN MOLECULAR MEDICINE

A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease

(2012) I. H. Richard et al.   NEUROLOGY

Glutamate NMDA receptor dysregulation in Parkinson’s disease with dyskinesias

(2011) Imtiaz Ahmed et al.   BRAIN

Serum Cholesterol and the Progression of Parkinson's Disease: Results from DATATOP

(2011) Xuemei Huang et al.   PLoS One

Clinical risk-benefit assessment of dopamine agonists

(2008) J. C. Möller et al.   EUROPEAN JOURNAL OF NEUROLOGY

Levodopa-Induced Dyskinesias in Parkinson’s Disease: Etiology, Impact on Quality of Life, and Treatments

(2008) Elmyra V. Encarnacion et al.   EUROPEAN NEUROLOGY

Role of homocysteine in the treatment of Parkinson's disease

(2008) Thomas Müller   Expert Review of Neurotherapeutics

A controlled trial of antidepressants in patients with Parkinson disease and depression

(2008) M. Menza et al.   NEUROLOGY

Interactions between antiparkinsonian drugs and ABCB1/P-glycoprotein at the blood–brain barrier in a rat brain endothelial cell model

(2008) Sarah Vautier et al.   NEUROSCIENCE LETTERS

Long-term outcome in Parkinson disease: no advantage to initiating therapy with dopamine agonists

(2008) Kathleen M Shannon   Nature clinical practice. Neurology